Comparative Effects of Dopaminergic Agonists on Cardiovascular, Renal, and Renin-Angiotensin Systems in Hypertensive Patients
Authors:
- 1 January 1992
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 32 (1) , 55-60
Abstract
The role of dopaminergic receptors on renal junction has been extensively studied. Recently dopaminergic receptor has been classified in two subtypes D1 and D2, which seem to have different modulatory junction. However, the role of dopaminergic receptors on cardiovascular junction and more specifically the potential role of dopaminergic agonists as antihypertensive agents has not yet been clarified. Nine outpatients with mild and moderate hypertension were studied in the Cardiology Service of Vargas Hospital with a D1 agonist, piribedil, at 50–100 mg/day, orally, for 8 weeks, and with a D2 agonist, bromocriptine, at 2.5–5 mg/day, orally, for an another 8 weeks by using a placebo comparative crossover design. Piribedil reduced blood pressure with a modest increase in heart rate, plasma renin activity, and of plasma aldosterone, and an important increment of renal junction. Bromocriptine reduced blood pressure with a decrease in heart rate and plasma aldosterone without altering renal junction. There was no orthostatic hypotension with either agent. The authors conclude that activation of dopaminergic D1 receptor induces a vasodilatory and antihypertensive effect with a reflex increase in sympathetic tone, whereas activation of dopaminergic D2 receptor induces a decrease in sympathetic tone, probably due to a decrease in norepinephrine release at adrenergic endings. The potential effect of these compounds as antihypertensive agents is of great interest because blood pressure reduction can be induced by a new mechanism, i. e. activation of dopaminergic receptors which results in a decrease of the renin angiotensin system or a vasodilatory action. This study determined the cardiovascular actions of both dopaminergic agonists bromocriptine and piribedil and dejined the potential antihypertensive effect of these compounds; determined the influence of these compounds on the renin angiotensin system and the cardiovascular and renal systems; and defined drug tolerance.Keywords
This publication has 21 references indexed in Scilit:
- Involvement of dopamine receptor subtypes in dopaminergic modulation of aldosterone secretion in ratsLife Sciences, 1987
- Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in ratsEuropean Journal of Pharmacology, 1983
- Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents: Part I: Subclassification and functional descriptionLife Sciences, 1982
- Peripheral dopamine receptor identification: Properties of a specific dopamine receptor in the rat adrenal zona glomerulosaBiochemical and Biophysical Research Communications, 1981
- Dopaminergic control of sympathetic tone and blood pressure: evidence in primary hypertension.Hypertension, 1980
- Ergot alkaloids: Interaction with presynaptic dopamine receptors in the neostriatum and olfactory tuberclesEuropean Journal of Pharmacology, 1980
- Evaluation of a new commercial radioassay kit for aldosterone using an iodinated tracerClinical Biochemistry, 1979
- Bromocriptine is a potent α-adrenoceptor antagonist in the perfused mesenteric blood vessels of the ratJournal of Pharmacy and Pharmacology, 1978
- HYPERPROLACTINÆMIA AND ANTIHYPERTENSIVE EFFECT OF BROMOCRIPTINE IN ESSENTIAL HYPERTENSION Identification of Abnormal Central Dopamine ControlThe Lancet, 1977
- Effects of piribedil on noradrenaline and MOPEG-SO4 levels in the rat brainEuropean Journal of Pharmacology, 1974